Phase II Safety and Efficacy Study of Single-Agent AT-101 in Patients With Relapsed or Refractory B-Cell Malignancies - Related Studies

Phase II Safety and Efficacy Study of Single-Agent AT-101 in Patients With Relapsed or Refractory B-Cell Malignancies

This study has been completed.

Study NCT00275431. Last updated on June 5, 2008. Information provided by Ascenta Therapeutics

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Follicular Lymphoma
		Diffuse Large Cell Lymphoma
		Mantle Cell Lymphoma
		Small Lymphocytic Lymphoma
		Chronic Lymphocytic Leukemia

2	Additional conditions recognized in this trial
		Leukemia
		Leukemia, B-Cell
		Leukemia, Lymphocytic, Chronic, B-Cell
		Leukemia, Lymphoid
		Lymphoma
		Lymphoma, Follicular
		Lymphoma, Large B-Cell, Diffuse
		Lymphoma, Mantle-Cell

3	More general conditions related to this trial
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphatic Diseases
		Lymphoma, B-Cell
		Lymphoma, Non-Hodgkin
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type

4	Interventions listed in this trial
		AT-101

5	Sponsors listed in this trial
		Ascenta Therapeutics